XML 80 R66.htm IDEA: XBRL DOCUMENT
v2.4.0.8

LICENSE AGREEMENTS (Details) (USD $) | 12 Months Ended | 0 Months Ended
--- | --- | ---
Dec. 31, 2011 | Dec. 31, 2013 License agreements GE Healthcare UK Limited | Dec. 31, 2012 License agreements GE Healthcare UK Limited | Dec. 31, 2011 License agreements GE Healthcare UK Limited | Jan. 05, 2011 License agreements Angiochem | Dec. 06, 2010 License agreements Angiochem | Dec. 05, 2012 License agreements TA Sciences
LICENSE AGREEMENTS |  |  |  |  |  |  |
Revenues from collaborative agreements | $ 300,000 | $ 0 | $ 0 | $ 300,000 |  |  |
License fee revenue |  | 0 | 825,000 | 350,000 |  |  |
Paid upfront payment in cash |  |  |  |  |  | 7,500,000 |
Issuance of common stock for acquired in-process research and development | 27,500,000 |  |  |  | 27,500,000 |  |
Total upfront payment relating to acquired in-process research and development expensed |  |  |  |  |  | 35,000,000 |
Shares of common stock issued against acquired in-process research and development |  |  |  |  | 5,261,144 |  |
Number of days to be considered for closing price of common stock |  |  |  |  | 5 days |  |
Issuance of common stock for acquired in-process research and development | 28,094,000 |  |  |  | 28,094,000 |  |
Acquired in-process research and development expense |  |  |  |  | 594,000 |  |
Non-refundable upfront payment recognized in other income |  |  |  |  |  |  | $ 2,500,000

X
- Definition Represents the number of days used to calculate the volume weighted average closing price of common stock immediately preceding the issuance date used to determine number of shares to be issued under collaborative arrangement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementsDaysUsedToCalculateWeightedAverageClosingPricePriorToIssuanceDateUsedToDetermineNumberOfSharesToBeIssued
Namespace Prefix: | gern_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents incremental amount of acquired in-process research and development expense recognized for the excess of the fair market value of common stock issued resulting from the difference between the five-day volume weighted average closing price and the closing price on the date of issuance. + References No definition available. + Details
Name: | gern_IncrementalAcquiredInProcessResearchAndDevelopmentExpense
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront payments for research and development assets that were acquired in a transaction other than a business combination. + References No definition available. + Details
Name: | gern_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffUpfrontPayment
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of shares of stock issued during the period as part of a transaction to acquire research and development assets that do not qualify as a business combination. + References No definition available. + Details
Name: | gern_StockIssuedDuringPeriodValuePurchaseOfResearchAndDevelopmentAssets
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_ContractsRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.4) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 4 -Article 7 + Details
Name: | us-gaap_OtherIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration